Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Hematology

• Publication date

  2000-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10245332.2000.11746530PMID 27420926
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic and Pharmacodynamic Considerations

  2006cited by this paper
• Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.

  2000cited by this paper
• The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines.

  2000cited by this paper
• P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.

  2000cited by this paper
• P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death

  1999cited by this paper
• Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

  1999cited by this paper
• Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)

  1999cited by this paper
• Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

  1999cited by this paper
• Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

  1999cited by this paper
• P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death.

  1999cited by this paper
• Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines*

  1998cited by this paper
• Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

  1998cited by this paper
• Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines.

  1998cited by this paper
• Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.

  1998cited by this paper
• Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.

  1998cited by this paper
• Multidrug resistance mediated by the ATP‐binding cassette transporter protein MRP

  1998cited by this paper
• Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.

  1998cited by this paper
• Overexpression of lung‐resistance protein and increased P‐glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival

  1998cited by this paper
• Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study

  1998cited by this paper
• The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis.

  1998cited by this paper
• Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations.

  1997cited by this paper
• Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines

  1997cited by this paper
• MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

  1997cited by this paper
• Mechanisms of drug resistance in hematologic malignancies.

  1997cited by this paper
• Expression of the human major vault protein LRP in acute myeloid leukemia.

  1997cited by this paper
• Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

  1997cited by this paper
• The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.

  1997cited by this paper
• Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.

  1997cited by this paper
• Intermittent exposure to doxorubicin in vitro selects for multifactorial non‐P‐glycoprotein‐associated multidrug resistance in RPMI 8226 human myeloma cells

  1997cited by this paper
• Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines

  1997cited by this paper
• Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.

  1997cited by this paper
• Multicentric evaluation of the MDR phenotype in leukemia

  1997cited by this paper
• Retrovirus-Mediated Gene Transfer of the Multidrug Resistance-Associated Protein (MRP) cDNA Protects Cells from Chemotherapeutic Agents

  1997cited by this paper
• The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance.

  1997cited by this paper
• Allogeneic transfusion and infection: economic and clinical implications.

  1997cited by this paper
• Non-P-glycoprotein drug export mechanisms of multidrug resistance.

  1997cited by this paper
• Verapamil suppresses the emergence of P‐glycoprotein‐mediated multi‐drug resistance

  1996cited by this paper
• Influence of Cluster Formation of Acidic Phospholipids on Decrease in the Affinity for ATP of DnaA Protein (*)

  1996cited by this paper
• Tissue distribution of the multidrug resistance protein.

  1996cited by this paper
• Double knockout of the MRP gene leads to increased drug sensitivity in vitro.

  1996cited by this paper
• Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines.

  1996cited by this paper
• The anthracycline resistance-associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia cell line.

  1996cited by this paper
• Coordinated Induction of MRP/GS-X Pump and γ-Glutamylcysteine Synthetase by Heavy Metals in Human Leukemia Cells*

  1996cited by this paper
• Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance‐associated protein

  1996cited by this paper
• Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.

  1996cited by this paper
• Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.

  1996cited by this paper
• Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

  1996cited by this paper
• How does the MRP/GS-X pump export doxorubicin?

  1996cited by this paper
• Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.

  1995cited by this paper
• Expression pattern of MRP in human tissues and adult solid tumor cell lines.

  1995cited by this paper
• Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.

  1995cited by this paper
• Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.

  1995cited by this paper
• P-glycoprotein and cell volume-activated chloride channels

  1995cited by this paper
• The drug resistance-related protein LRP is the human major vault protein

  1995cited by this paper
• A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

  1995cited by this paper
• Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.

  1995cited by this paper
• The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification.

  1995cited by this paper
• ATP‐dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion

  1995cited by this paper
• Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter.

  1995cited by this paper
• Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells.

  1994cited by this paper
• MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.

  1994cited by this paper
• Glutathione-associated enzymes in anticancer drug resistance.

  1994cited by this paper
• Clinical relevance of P-glycoprotein expression in haematological malignancies.

  1994cited by this paper
• Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.

  1994cited by this paper
• Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications.

  1994cited by this paper
• MDR1 gene expression in chronic lymphocytic leukemia.

  1994cited by this paper
• Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

  1994cited by this paper
• P-glycoprotein expression and function in circulating blood cells from normal volunteers.

  1994cited by this paper
• The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.

  1994cited by this paper
• Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance.

  1994cited by this paper
• Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.

  1994cited by this paper
• Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex.

  1993cited by this paper
• P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.

  1993cited by this paper
• P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy

  1993cited by this paper
• The multidrug resistance (mdr1) gene product functions as an ATP channel.

  1993cited by this paper
• Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL).

  1993cited by this paper
• Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

  1993cited by this paper
• Modulation of multidrug-resistant multiple myeloma by cyclosporin

  1992cited by this paper
• Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

  1992cited by this paper
• Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.

  1992cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.

  1992cited by this paper
• Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

  1992cited by this paper
• Unlocking vaults: organelles in search of a function.

  1991cited by this paper
• P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

  1991cited by this paper
• Expression of Multidrug Resistance Gene in Human Cancers

  1989cited by this paper
• Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

  1989cited by this paper
• Reversal of drug‐resistance in multiple myeloma with verapamil

  1988cited by this paper
• Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.

  1987cited by this paper
• Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA

  1986cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper

• Drug resistance to topoisomerase directed chemotherapy in human multiple myeloma

  2008cites this paper
• Vincristine resistance development in lymphoblastoid cells under conditions of selective P-glycoprotein inhibition

  2005cites this paper